MarketPulse
C

$CYTK

6 articles found
2 positive
0 negative
4 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cytokinetics Q1 2026 Results Due May 5; MYQORZO® Updates Expected

Cytokinetics will report Q1 2026 earnings May 5, discussing MYQORZO® commercialization and pipeline progress in heart failure treatments.
CYTKearnings reportheart failure
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biohaven Stock Crashes 70%, but $6M Insider Bet Hints at Turnaround Play

Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.
CYTKBHVNNBIXstock declineFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cytokinetics Awards Stock Incentives to Five New Hires Under Nasdaq Rules

Cytokinetics granted inducement stock options and RSUs to five new employees hired in early 2026, using Nasdaq listing rule 5635(c)(4) to compensate talent.
CYTKvesting schedulestock options
The Motley FoolThe Motley Fool··Sara Appino

Cytokinetics Executive Cashes In $929K Options as Cardiac Drug Launches

Cytokinetics insider Andrew Callos sold $929K in stock options weeks after FDA approval of heart drug myqorzo, reducing holdings by 23%.
CYTKFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Cytokinetics, Incorporated

Cytokinetics Launches MYQORZO Following FDA Approval, Guides 2026 Spending

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.
SNYBAYRYCYTKFDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Custom Market Insights

ALS Therapeutics Market Poised to More Than Double by 2035

ALS therapeutics market to more than double by 2035, reaching $1.96 billion. Growth driven by genetic therapies, improved diagnostics, and disease awareness.
CYTKBIIBIONSAMLXrare diseasegene therapy